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Malignant melanoma is one of the most fascinat-
ing tumors to study from the immunologic stand-
point. Many lines of evidence suggest that the host 
does mount an immune response to his melanoma. 
The incidence of partial regression of primary 
malignant melanomas has been estimated to be as 
high as 15% [1, 2]. Frequently there is a vigorous 
host response present in the primary lesion. The 
occurrence of halo nevi and of vitiligo in patients 
with melanoma further suggests an immune re-
sponse involving the pigment-producing cells. It is 
not unusual for patients to undergo a protracted 
course with ongoing disease or to have a remission 
of many years following excision of the primary 
lesion before recurrence of disease. 
The observation that a blood transfusion from a 
donor who had undergone spontaneous regression 
of malignant melanoma appeared to cause regres-
sion in a patient with disseminated melanoma [3] 
further stimulated interest in the immunology and 
potential of immunotherapy for this disease. 
PATHOLOGY 
Many investigators have contributed to our 
current understanding of the pathology of malig-
nant melanoma, and the work of Clark et al [4] 
clearly delineated histologic factors relevant to 
determining prognosis. It is this understanding of 
the pathology 6f the tumor which makes possible 
rationally designed immunotherapy protocols. 
Clark et al [4] distinguished the three types of 
melanoma: superficial spreading, nodular, and 
lentigo maligna melanoma. The superficial spread-
ing melanoma characteristically undergoes a pe-
riod of superficial radial growth before entering the 
penetrating vertical growth phase, whereas the 
nodular melanoma lacks this characteristic and 
undergoes vertical growth early in the course. 
These different patterns of growth result in the 
distinctive clinical and histologic features of these 
lesions. The radial growth pattern of the superficial 
spreading melanoma makes wide local excision of 
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importance in this lesion. Lentigo maligna mela-
noma usually occurs in older individuals and is 
considered to carry a better prognosis than the 
other two types. 
For patients with either superficial spreading or 
nodular melanoma, the prognosis is correlated with 
the depth of invasion, regardless of the type of 
lesion (Tab.); it ranges from excellent, with lesions 
invasive to level II, to progressively poorer for the 
more deeply invasive levels. More recently, others 
have stressed the additional factor of tumor thick-
ness as a correlate of prognosis [5, 6]. 
Other features which affect prognosis include sex 
(the prognosis being better in females), and the 
presence or absence of regional metastases. The 
presence of an inflammatory infiltrate indicates an 
improved prognosis; but if the infiltrate consists of 
plasma cells, the prognosis is worse. Pedunculated 
lesions carry a poor prognosis. 
IMMUNOLOGIC EVALUATION 
Skin Test Reactivity 
Cutaneous reactivity to standard skin test anti-
gens has been found to be normal in three studies 
of patients with malignant melanoma, even in 
those with widely disseminated disease [7, 8, 
Spitler, unpublished observations] and was found 
to be diminished in one study [9]. However, all of 
the patients in the latter study had received prior 
chemotherapy or radiation. 
There have been a limited number of studies in 
which skin test reactivity to melanoma antigens has 
been evaluated. Stewart [10] demonstrated that 
about 25% of patients show skin reactivity to 
tumor extracts and observed a correlation between 
host response in the tumor specimen and skin test 
reactivity to autologous tumor extracts [11]. In a 
study of skin reactivity to extracts of autologous 
malignant melanoma cells Fass et al [7] found 
positive responses in 3 of 8 patients. Those showing 
reactivity were patients with localized disease; 
patients with disseminated disease lacked reactiv-
ity to tumor antigen but not to other antigens. 
Hollinshead et al [12] reported the partial purifi-
cation of a melanoma-associated antigen which 
elicited skin reactivity in 17 of 22 patients with 
early melanoma, in 7 of 19 patients with late 
melanoma, and in only 1 of 22 control subjects. 
Char et al [13] found skin reactivity to a similarly 
prepared soluble melanoma antigen in 18 of 19 
patients with early ocular melanoma and in none 
of 12 subjects without melanoma. 
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TABLE. Classification of malignant melanoma 
Level of Histologic character invasion Deaths Survivors Other
a 
% % % 
II Through basement membrane 8 72 19 
into papillary dermis 
III Up to the reticular dermis 35 46 18 
IV Into reticular dermis 46 32 22 
V Into subcutaneous fat 46 32 22 
a Lost to follow-up or dead without evidence of melanoma (extracted from Clark et al [4]) 
Lymphocyte Stimulation 
Jehn et al [14] observed very high degrees of 
lymphocyte stimulation by cyst fluid from a malig-
nant m~lanoma and by extracts of autologous 
tumors ill 7 of 7 patients with malignant mela-
noma. All of these patients had metastatic disease 
and some had received chemotherapy. Savel [15] 
reported a positive response in 1 of 3 patients with 
~elanoma, and Mavligit et al [16] observed posi-
tive re~ponses in 3 of 6 patients. In the latter study, 
the skm test response to the tumor cell extract did 
not seem to correlate particularly well with the 
lymphocyte response in vitro to the same antigen. 
In our own studies, lymphocyte stimulation was 
determined in 72 patients with melanoma and in 
no~mal control subjects. The antigen used was a 
salme extract of malignant melanoma. Positive 
responses (over 5-fold stimulation) were observed 
in 20% of patients and in 5% of control subjects. In 
our hands, the lymphocyte stimulation test seems 
to be the best in vitro correlate of the clinical 
course: Of 72 patients studied, the highest degrees 
of lymphocyte stimulation were observed in 2 
patients who were subsequently found to be under-
?oing partial spontaneous regression; an increase 
m lymphocyte stimulation in response to mela-
noma ~ntigens occurre.d in 2 patients undergoing 
regresslOn of metastatIc melanoma coincident in 
timing with the administration of transfer factor 
(TF), but it did not occur in 8 other patients who 
rec~ived TF.and whose lesions did not regress [17]; 
an mcrease m lymphocyte stimulation in response 
to melanoma antigens occurred in 3 of 4 patients 
responding to intralesional injections of bacillus 
C.almette-Guerin (BCG), but not in 2 patients who 
dId not respond to this treatment; and the donor of 
T~ . for the patients who appeared to respond 
cl~nIcall~ ha.d the highest degree of lymphocyte 
stImulatlOn m response to melanoma antigens of 
any donor [17]. 
Macrophage or Leukocyte Migration Inhibition 
Cochr~n et al [18] studied reactivity using anti-
gens deflve~ fr~~ ~O malignant melanomas. Using 
the test for mhIbitIon of leukocyte migration from 
c~pillary ~ubes, they found that 80% of 46 patients 
wI~h malIgnant. melanoma showed reactivity to 
thIS panel of antIgens and that there was a signifi-
c~nt fal~ in reactivity in the immediate postopera-
tIve penod. He also observed reactivity in 5 of 31 
normal control subjects. 
.Falk. et al J19] reported inhibition of leukocyte 
migratlOn usmg a preparation of membrane anti-
gens from three melanomas. Positive responses 
were observed in 16 of 18 patients with "active 
melanoma," in 4 of 12 patients with "arrested 
melanoma," and in none of the normal control 
subjects or patients with other tumors. Addition of 
autologous serum abrogated the response in the 
patients with malignant melanoma. 
.Although the capillary tube method of leukocyte 
migratio? inhibition appears reliable for particu-
late antIgens, many investigators have failed to 
observe a correlation between capillary tube leuko-
cyte migration inhibition and skin test reactivity 
when soluble antigens were used. In contrast, we 
have regularly observed excellent correlations be-
tween skin tests and inhibition of leukocyte migra-
tion by soluble antigen when the agarose plate 
technique is used [20]. Indeed, analysis of data ob-
tained in our laboratory in more than 100 tests 
using standard skin test antigens indicates a 90% 
correlation between inhibition of leukocyte migra-
tion and skin test reactivity. The occasional lack of 
correlation is due to the occurrence of false nega-
tive results in the leukocyte migration test; we 
have not yet observed a false positive result. 
Accordingly, we applied the agarose plate leuko-
c~te migration test to the evaluation of patients 
WIth melanoma. Inhibition of migration by mela-
noma antigens was observed in 20% of patients and 
22% of normal controls. Using the standard indirect 
~a~r?l?hage migration inhibitory test, migration 
mhibitlOn was produced by melanoma antigens in 
38% of patients and in 23% of normal controls. Of 
11 family members of patients with melanoma 8 , 
produced migration inhibitory factor (MIF) in re-
sponse to melanoma antigens. 
Anal~sis of ou~ ~ata ~ndicates that the following 
tests dId not dIstmgUIsh between patients with 
malignant melanoma and control subjects and did 
not correlate with stage of disease or prognosis: 
skin test reactivity, production of MIF and inhibi-
. ' bon of leukocyte migration by melanoma antigens. 
Lymphocyte stimulation by melanoma antigens 
ma~ ~rove to ~e the best predictor of in vitro prog-
nOSIS m that hIgh levels of lymphocyte stimulation 
Sept. 1976 
in response to tumor-associated antigens may be 
correlated with tumor regression. 
Cytotoxicity 
Many investigators have demonstrated that 
lymphocytes from patients with malignant mela-
noma may show specific cytotoxicity for melanoma 
cells. One study demonstrated that these cells were 
located in the T-cell fraction [21], and a second 
study demonstrated them to be non-T cells [22]. 
Lymphocytes from patients with advanced mela-
noma were found to be less reactive than those 
from patients with a small tumor load [23]. Pa-
tients with progressively growing melanomas may 
have a factor in their serum which inhibits or blocks 
the cytotoxic activity of lymphocytes, and patients 
free of melanoma may have a serum factor which 
abrogates this blocking activity [23, 24]. Recent 
studies have raised questions as to whether or not 
the observed cytotoxicity is specific [24, 26]. 
Antibody Studies 
Several investigators have reported the presence 
of antibodies directed toward tumor-associated 
antigens in the sera of patients with malignant 
melanoma as detected by immunofluorescence 
[27 -30]. The percentage of positive responses in 
patients with melanoma and in control subjects 
varies considerably in these studies. Lewis et al 
[31] reported that the antibodies are present most-
ly in patients with localized disease, and disappear 
as dissemination occurs. A possible explanation for 
this apparent loss of antibody was the development 
of an anti-idiotype antibody [32] . 
Lewis et al [33] and Lewis and Phillips [34] have 
further provided evidence for a number of different 
tumor-associated antigens and proposed the ap-
pearance of antibodies to these various antigens 
at different times in the course of disease. 
More recently, questions have been raised 
regarding the specificity and reliability of the 
immunofluorescent test for detection of antimela-
noma antibodies [35; 36; M. Abel and J.-C. 
Bystryn, in preparation ]. Wood and Barth [35] 
found no significant difference in the percentage 
of positive reactions toward a panel of melanoma 
cells obtained with sera from patients with mela-
noma, patients with other tumors, or normal 
donors. Sera from patients with melanoma did 
have higher titers than the control sera, however. 
Others found that there was good agreement when 
tests were performed in replicate and read by two 
observers, but that there was a considerable in-
crease in variability when tests were done on 
different days or with different substrates [36; M. 
Abel and J .-C. Bystryn, in preparation]. Further, 
there was poor replication of results when different 
teams performed the same tests on the same day 
using the same reagents. 
Lewis et al [30] further reported the presence of 
complement-dependent cytotoxic antibodies in the 
sera of patients with localized disease, but not in 
MALIGNANT MELANOMA 437 
the sera of those with disseminated disease. This 
observation has recently been confirmed [37]. 
CHEMOTHERAPY 
In patients with disseminated disease, therapy 
with imidazole carboxamide (DTIC) results in a 
23% response rate [38, 39). Following initiation of 
chemotherapy, the I-year survival rate is 15 %. 
Therapy with a combination of agents results in 
little, if any, improvement in these statistics [38]. 
These data make it obvious as to why there is so 
much interest in attempting to provide better 
means of therapy through immunotherapeutic ap-
proaches. 
CHEMOIMMUNOTHERAPY 
Gutterman et al [40) compared chemoim-
munotherapy with the combination of DTIC and 
BCG with results obtained in a historic control 
group receiving chemotherapy alone. Many ques-
tions have been raised concerning the design of this 
study; however, one observation that does appear 
important is that patients with lymph node metas-
tasis who were treated with chemoimmunotherapy 
experienced a 55% remission rate, whereas those 
treated with chemotherapy alone had an 18% 
response rate. 
IMMUNOTHERAPY 
BCG 
The results of studies of BCG in cancer have 
recently been reviewed [41]. One study has shown 
that sensitization with BCG induced specific pro-
tection against melanoma in mice, suggesting that 
there may be antigens which cross-react between 
BCG and melanoma [42]. 
BCG has been rather widely used in the ther-
apy of patients with malignant melanoma. In the 
opinion of this author there have not yet been any 
appropriately designed and controlled studies that 
have answered the question as to whether or not 
the administration of BCG by scarification causes 
clinical benefit in patients with malignant mela-
noma. Such studies are currently under way and 
the answers should be forthcoming within the next 
few years. 
There is one instance in which administration of 
BCG may prove to be the treatment of choice: for 
the intralesional injection of multiple recurrent 
subcutaneous nodules. The theory of using intrale-
sional BCG rather than surgical removal of multi-
ple recurrent subcutaneous nodules is based on the 
possibility that the injection of BCG into the tumor 
will produce an adjuvant effect to enhance tumor 
immunity and perhaps diminish the likelihood of 
recurrences. Patients for this therapy should be 
carefully evaluated for visceral disease, including 
liver, bone, and brain scan, and only those free of 
visceral disease should be selected. This extreme 
selectivity is necessary because visceral lesions do 
not regress with injections of cutaneous lesions. 
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Morton et al [43] reported regression of 91 % of 
nodules directly injected with BCG; 17 % of unin-
jected nodules in their patients also underwent 
regression. Thirty-one percent of these patients 
had no evidence of disease 6 to 74 months after 
treatment. 
There are two types of BCG currently commer-
cially available in the U.S .; one is prepared by the 
Eli Lilly Company, and the other, which is 200 
times as potent as the Lilly preparation, is pre-
pared by Chicago Research Laboratories. Side ef-
fects of the intralesional injection of BCG are com-
mon and consist of chills, fever, and occasional 
hypotension following the injection. Local reaction 
may be intense and lead to ongoing inflammation, 
tissue breakdown, and drainage. Hepatic granu-
lomas are a late sequelae. Two deaths have been 
reported which appear to have been due to the 
BCG injection [44]. 
Transfer Factor (TF) 
TF is a dialyzable extract of sensitized leuko-
cytes that transfers skin test reactivity from a 
positive donor to a previously negative recipient 
[45, 46]. In normal subjects, administration of TF 
also transfers other parameters of cellular immu-
nity, including stimulation of lymphocytes and 
production of MIF in response to specific antigens. 
TF is extremely potent: the amount derived from 
leukocytes in approximately 20 ml of blood is suf-
ficient to confer systemic reactivity in normal re-
cipients [47]. TF does not transfer the ability to 
produce antibodies [48]; hence , in patients with 
malignancy, it does not carry the hazard of induc-
ing antibodies, such as enhancing antibodies , 
which might have an adverse effect on the patient. 
Brandes et al [49] reported partial regression of 
metastatic malignant melanoma in 1 of 2 patients 
treated with TF, and Thompson [50] also reported 
a beneficial effect of TF in patients with malignant 
melanoma. LoBuglio et al [51] have used TF in 
patients with sarcoma, and Levin et al [52] have 
reported clinical improvement in patients with 
osteogenic sarcoma treated with TF derived from 
family members shown by tests in vitro to have 
cellular immunity to osteogenic sarcoma cells. Two 
additional groups have reported clinical benefit to 
patients given TF [53] or lymphocytes [54] derived 
from donors sensitized to the patient's tumor. 
We have used combined immunotherapy with 
TF and BCG given by scarification to treat 6 
patients with disseminated malignant melanoma 
which was not widespread. Of 6 patients treated, 2 
had complete regression of all tumor nodules coin-
cident with TF therapy. One had recurrence of 
tumor; in spite of continued therapy, she devel -
oped cerebral metastases and died. The second 
patient remains completely free of demonstrable 
disease two years later. 
Lymphocyte stimulation by melanoma antigens 
was useful for evaluation in that the only patient 
whose stimulation increased after TF were the two 
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whose lesions regressed. There was no consistent 
change in cellular immunity to melanoma antigens 
as measured by the indirect test for MIF, or by 
inhibition of leukocyte migration. Similarly, there 
was no consistent change in the percentage of 
rosette-forming cells. The results of this study are 
sufficiently encouraging to warrant a controlled 
double-blind study of the effects of TF in dis-
seminated malignant melanoma. Problems to be 
resolved include the best means for selection of 
donors , and optimal timing and dosage of TF 
administration . 
Leuamisole 
The laevo-isomer of the drug 2,3,5,6, -tetrahy-
dro-6-phenylimidazo (2,I-b) thiazole hydrochlo-
ride (levamisole , Fig.) has been widely used as an 
antihelmint hic . An incidental observation in 1971 
led to the discovery that levamisole increases both 
cellular and humoral immune responses as well as 
having other immunologic effects, such as stimula-
tion of reticuloendothelial activity and of phagocy-
tosis. When added to lymphocyte cultures, it in-
creases the response to suboptimal doses of anti-
gen or phytohemagglutinin (PHA). It was further 
found to inhibit tumor growth in some experimen-
tal animal tumors [55-57], although the effect was 
variable in others . In uncontrolled studies, it was 
reported to cure or to decrease the frequency and 
severity of lesions in patients with recurrent aph-
thous stomatitis or recurrent herpes labialis and to 
cause clinical improvement in patients with rheu-
matoid arthritis . It has further been reported to be 
effective in the therapy of Job's syndrome, re-
gional enteritis, chronic active hepatitis, and malig-
nancy. 
Levamisole is easy to administer, being given in 
pill form in intermittent courses, a~d its .si?e 
effects are minimal. In our own studIes, deflllIte 
clinical improvement was noted. in patients with 
herpes simplex of the cornea and with aphthous 
stomatitis. Encouraging but not yet definitive re-
sults were also observed in patients with rheuma-
toid arthritis, toxoplasmic retinochoroiditis, herpes 
labialis, and herpes progenitalis. Im~unolo~ic 
effects in these patients were rather conSIstent lll-
creases in skin test reactivity. Definite changes 
were also noted in the in vitro tests, including PHA 
response, lymphocyte stimulation by specific anti-
H N S 
>----0' ~yj.HCI 
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(2, l-b) thiazolehydrochloride 
FIG. Structure of the drug levamisole. 
Sept. 1976 
gen, leukocyte migration inhibition, and rosette-
forming cells. The nature of these changes de-
pends on the disease being studied. 
In our studies of a malignant melanoma in the 
hamster, definite regression of established tumors 
has been observed following the administration of 
levamisole (spontaneous regression does not occur 
in this system). 
The results in the animal systems, combined 
with the evidence of efficacy in human diseases 
thought to be related to immunodeficiency, make it 
possible that this drug may prove efficacious as an 
immunotherapeutic agent in patients with malig-
nancy. 
SUMMARY 
Recent advances in our understanding of the 
pathology and prognosis of malignant melanoma 
make possible rationally designed immunothera-
peutic studies. A number of immunologic studies 
suggest that there may be a specific immune re-
sponse to melanoma-associated antigens in pa-
tients with melanoma; however, other studies have 
shown lack of specificity, so this issue remains to 
be definitively resolved. New immunotherapeutic 
agents, including BeG, TF, and levamisole, among 
others, offer the potential for improving therapy 
for patients. 
REFERENCES 
1. Little JH: Pathology 3:62, 1971 
2. McGovern VJ: In Melanoma and Skin Cancer. Edit-
ed by WH McCarthy. Sydney, Australia, VCN 
Blight, Government Printer, 1972, p 95 
3. Sumner WC, Foraker AC: Cancer 13:79, 1960 
4. Clark WH Jr, From L, Bernardino E , Mihm MC: 
Cancer Res 29:705, 1969 
5. Breslow A: Ann Surg 172:902, 1970 
6. Wanebo HJ, Woodruff J, Fortner JG: Cancer 35:666, 
1975 
7. Fass L, Ziegler JL, Herberman RB, Kiryabwire 
JWM: Lancet 1:116, 1970 
8. Ziegler JL, Lewis MG, Luyombya JMS , Kiryabwire 
JWM: Br J Cancer 23:729, 1969 
9. Seigler HF, Shingleton WW, Metzgar RS, Buckley 
CE, Bergoc PM, Miller DS, Fetter BF, Phaup MB: 
Surgery 72: 162, 1972 
10. Stewart THM: Cancer 23:1368, 1969 
11. Stewart THM: Cancer 23:1380, 1969 
12. Hollinshead AC , Herberman RB, Jaffurs WJ, Alpert 
LK, Minton JP, Harris JE: Cancer 34:1235, 1974 
13. Char DH, Hollinshead A, Cogan DG, Ballintine EJ, 
Hogan MJ, Herberman RB: N Engl J Med 291:274, 
1974 
14. Jehn UW, Nathanson L, Schwartz RS, Skinner M: N 
Engl J Med 283:329, 1970 
15. Savel H: Cancer 24:56, 1969 
16. Mavligit GM, Ambus U, Gutterman JU, Hersh EM, 
McBride CM: Nature [New BioI] 243:188, 1973 
17. Spitler LE, Levin AS, Wybran J: Cell Immunol 
21:358, 1976 
18. Cochran AJ, Spilg WGS, Mackie RM, Thomas CE: 
Br Med J 4:67, 1972 
19. Falk RE, Mann P, Langer B: Arch Surg 107:261, 1973 
20. Astor SH, Spitler LE, Frick OL, Fudenberg HH: J 
Immunol 110: 1174, 1973 
21. Wybran J, Hellstrom I, Hellstrom KE, Fudenberg 
MALIGNANT MELANOMA 439 
HH: Int J Cancer 13:515, 1974 
22. de Vries JE, Cornain S, Rumke P: Int J Cancer 
14:427, 1974 
23. Hellstrom I, Hellstrom KE: Fed Proc 32:156, 1973 
24. Hellstrom I, Sjogren HO, Warner GA, Hellstrom KE: 
Int J Cancer 7:226, 1971 
25. Takasugi M, Mickey MR, Terasaki PI: Cancer Res 
33:2898, 1973 
26 . Heppner G, Henry E, Stolbach L, Cummings F, 
McDonough E, Calabresi P: Cancer Res 35:1931, 
1975 
27. Morton DL, Malmgren RA, Holmes EC, Ketcham 
AS: Surgery 64:233, 1968 
28. Muna NM, Marcus S, Smart C: Cancer 23:88, 1969 
29. Romsdahl MM, Cox IS: Surg Forum 20:126, 1969 
30. Lewis MG, Ikonopisov RL, Nairn RC, Phillips TM, 
Hamilton Fairley G, Bodenham DC, Alexander P: 
Br Med J 3:547, 1969 
31. Lewis MG, McCloy E, Blake J: Br J Surg 60:443, 
1973 
32. Lewis MG, Phillips TM, Cook KB, Blake J: Nature 
(Lond) 232:52, 1971 
33. Lewis MG, Avis PJG, Phillips TM, Sheikh KMA: 
Yale J BioI Med 46:661, 1973 
34. Lewis MG, Phillips TM: J Natl Cancer Inst 49:915, 
1972 
35. Wood GW, Barth RF: J Natl Cancer Inst 53:309, 1974 
36. Report from a Workshop on Fluorescent Antibody 
Studies in Human Malignant Melanomas, 1975. 
Available from Dr. Peter Dent, McMaster Univer-
sity, Hamilton, Ontario, Canada 
37. Bodurtha AJ, Chee DO, Laucius JF, Mastrangelo 
MJ, Prehn RT: Cancer Res 35: 189, 1975 
38. Luce JK: Cancer 30: 1604, 1972 
39. Einhorn LH, Burgess MA, Vallejos C, Bodey GP Sr, 
Gutterman J, Mavligit G, Hersh EM, Luce JK, 
Frei E III, Freireich EJ, Gottlieb JA: Cancer Res 
34:1995, 1974 
40 . Gutterman JU, Mavligit G, Gottlieb JA, Burgess 
MA, McBride CE, Einhorn L, Freireich EJ, Hersh 
EM: N Engl J Med 291 :592, 1974 
41. Bast RC Jr, Zbar B, Borsos T, Rapp HJ: N Engl J 
Med 290:1413, 1974 
42. Faraci RP, Barone JJ, Marrone JC, Schour L: J Natl 
Cancer Inst 52:1913, 1974 
43 . Morton DL, Eilber FR, Holmes EC, Hunt JS, Ketch-
am AS , Silverstein MJ, Sparks FC: Ann Surg 
180:635, 1974 
44. McKhann CF, Hendrickson CG, Spitler LE, Gun-
narsson A, Banerjee D, Nelson WR: Cancer 35:514, 
1975 
45. Lawrence HS: J Clin Invest 34:219, 1955 
46. Lawrence HS, AI-Askari S,David J, Franklin EC, 
Zweiman B: Trans Assoc Am Physicians 76:84, 
1963 
47. Lawrence HS: In Ciba Foundation Symposium on 
Cellular Aspects of Immunity. Edited by GEW 
Wolstenholme, M O'Conner. Boston, Little, 
Brown, 1960, p 243 
48 . Lawrence HS, Pappenheimer AM: J Clin Invest 
36:908, 1957 
49. Brandes LJ, Galton DAG, Wiltshaw E: Lancet 2:293, 
1971 
50. Thompson RB: Eur J Clin BioI Res 16:201, 1971 
51. LoBuglio AF, Neidhart JA, Hilberg RW, Metz EN, 
Balcerzak SP: Cell Immunol 7: 159, 1973 
52. Levin AS, Spitler LE, Wybran J , Byer VS, Fuden-
berg HH: Clin Res 21:648A, 1973 
53. Morse PA Jr, Deraps GD, Smith GV, Raju S, Hardy 
JD: Clin Res 21:71A, 1973 
54. Curtis JE: Proc Am AssocCancer Res 12:52A, 1971 
55. Renoux G, Renoux M: Nature [New BioI] 240:217, 
1972 
56. Chirigos MA, Pearson JW, Pryor J: Cancer Res 
33:2615, 1973 
57. Potter CW, Carr I, Jennings R, Rees RC, McGinty F, 
Richardson VM: Nature (Lond) 249:567, 1974 
440 SPITLER 
DISCUSSION 
Kirkpatrick: Can you add levamisole to lymphocyte 
cultures and see increased DNA synthesis in response to 
antigenic stimulation? With respect to your postulate 
that levamisole may act on cells other than lymphocytes, 
John Gallin and Daniel Wright and I have been studying 
the effects of levamisole on chemotaxis. It markedly en-
hances the response of monocytes and PMNs to stimu-
lants such as endotoxin-treated serum. 
Spitler: There have been publications demonstrating 
that addition of levamisole in vitro with suboptimal doses 
of antigen or PHA will increase the response to the level 
which is observed with optimal doses of antigen or PHA. 
We have performed in vitro studies and did not observe 
any change in the baseline cpm or increased reactivity 
when levamisole was added with optimal doses of antigen 
or mitogen. 
Gilliam: In the levamisole-treated patients with rheu-
matoid arthritis was there any effect on the serum 
concentration of rheumatoid factor? 
Spitler: These studies were done in collaboration with 
Drs. Basch and E. Engleman. In 2 patients the rheuma-
toid factor titer converted to negative during the course of 
levamisole therapy. Further, in 5 of 6 patients who had 
rheumatoid nodules, these nodules disappeared or be-
came smaller. 
Levis: In evaulating the effects of levamisole on skin 
tests, have you taken into account the effects of sequen-
tial skin tests alone? I know, for example, that rechal-
lenge with dinitrochlorobenzene produces several mea-
surable effects on the immune response [Levis et al: Clin 
Res 23: 584A, 1975]. 
Spitler: The question of the effect of sequential skin 
tests on cellular immune responses without intervening 
levamisole therapy is an extremely important one. We 
have not studied this in a manner analogous to that 
which was done in the patients receiving levamisole, but 
we are currently performing these studies. 
Sams: Did you look for the presence of blocking 
antibody in your patient with melanoma, and if so, how 
did the response to TF correlate with the presence of thE. 
antibody? 
Spitler: We did not study the occurrence of blocking 
antibody in the patients with melanoma. 
Bystryn: During the past year a number of studies 
have shown that lymphocytes of normal persons may 
react as commonly as those of melanoma patients when 
tested against melanoma cells by lymphocyte cytotoxic-
ity or macrophage inhibition. Can you tell us whether you 
have tested normal lymphocytes with your in vitro assays 
and what results you have obtained? 
Spitler: We examined in vitro reactivity to melanoma 
antigens in several groups of normal subjects. Some 
normal Caucasian subjects showed reactivity to mela-
noma antigens, but. the percent showing a positive re-
sponse was lower than the percent of melanoma patients 
or of household contacts responding. Because of the ob-
servations of the Hellstroms that cells from normal Black 
donors are cytotoxic for melanoma cells, we examined the 
reactivity of Black subjects as a separate group and found 
that they did not show reactivity to the melanoma 
antigen in these tests. Similarly most subjects with halo 
nevi (who did not have melanoma) did not show positive 
responses. 
Austen: Dr. Kirkpatrick, what is the effect of leva-
misole on cyclic nucleotides? 
Kirkpatrick: We have looked at the effects of levamis-
ole on cyclic nucleotides. In PMNs we see increments in 
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cGMP-on the order of 40 to 60%-but we do not have a 
positive control that tells us how great the maximal 
response in these cells is . Cyclic AMP levels decrease in 
these cells. Incidentally, the increase in cGMP accumula-
tion is seen only when the cells are incubated with 
imidazole . 
Austen: Dr. Spitler, why are you combining TF with 
BCG? 
Spitler: In the 6 patients with limited metastatic 
disease who were treated with TF and BCG, the BCG was 
given only by scarification and not by intralesional injec-
tion. This combination was used because we wanted to 
have the best chance for observing regression in patients 
with known metastatic disease. I do not know of any re-
ports in which BCG given by scarification has caused 
regression of metastatic lesions. The patient with the 
pulmonary and CNS lesion who also received surgery and 
CNS irradiation was presented only to demonstrate the 
inflammatory infiltrate which occurred in the pulmonary 
nodule following the systemic administration of TF. Her 
current survival, free of demonstrable disease, almost ~ 
years after excision of a cerebral metastasis is unusual, 
but studies in more patients will be required. Appro-
priate randomized, double-blind studies have been de-
signed to properly assess the results observed in these 
. preliminary investigations. 
Cohen: How close are workers in this area to develop-
in;; a preparation for TF therapy from a single or even 
limit"!d leukocyte types rather than from whole buffy 
coat? It would seem desirable to utilize a collection of 
lymphocytes devoid of contaminating lysosomal enzymes. 
Could not polymorphonuclear neutrophilic leukocytes on 
breakdown supply their granular proteases and in turn 
affect the very lymphocytic cellular material you are try-
ing to recover unchanged from its in vivo functional state? 
Shouldn't one be reluctant to intervene with immuno-
logic enhancAment in a disorder such as rheumatoid 
arthritis where there is evidence for the role of autoim-
mune phenomena in etiologic relationships? 
Spitler: We are not attempting to prepare TF from 
purified cell populations because it is not known which 
cell type the TF comes from. It is generally felt that it 
comes from the T -cells, but this has not been tested. It is 
my own bias that the TF may well come from macro-
phages. 
We were concerned with the possibility of enhancing 
. the immune response with levamisole in patients with 
rheumatoid arthritis, and this is the reason the study was 
not conducted on a randomized, double-blind basis from 
its initiation. We wanted to treat the first patients on an 
open basis so they could be closely watched for potential 
worsening of disease. 
Bystryn: Could you tell us what results you obtained 
with levamisole in patients with herpes simplex, particu-
larly in those with chronic recurrent disease? 
Spitler: Twenty-four patients with chronic recurrent 
herpes simplex infections have been treated. The results 
were most uniform in patients with herpes simplex of the 
cornea. Six patients with chronic ongoing infection of the 
cornea unresponsive to all standard therapy were treated 
and all became free of continuing infection with therapy. 
Eighteen patients with recurring labial or genital lesions 
were treated and 3/4 improved. This certainly does not 
demonstrate that levamisole is effective in this disease 
since the observed changes may represent spontaneous 
improvement or placebo effect. However, we do feel that 
these results are encouraging enough to warrant initiation 
of a randomized, double-blind study. 
Schwartzman: There have been a few reports in 
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veterinary medicine on the use of levamisole in immune 
deficiency diseases in animals. Additionally, the derma-
tology group at the Veterinary School of the University of 
Pennsylvania has had a limited experience with leva-
misole in the treatment of candidiasis, recurrent staphy-
lococcal pyoderma, and generalized demodectic mange. 
Complete clinical cures have been achieved in 4 canine 
cases of candidiasis affecting the skin and mucocutane-
ous junctions of the mouth and vulva when levamisole 
and Mycostatin were employed. These cases failed to re-
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spond previously to Mycostatin alone. We have been less 
successful in treating the latter 2 diseases. Though re-
markable results have been obtained in treating some of 
these patients with recurrent pyoderma and demodectic 
mange, there have been an equal number who failed to 
respond. These preliminary results have excited our 
interest in this drug; and we plan to continue and expand 
the investigation of its use in the treatment of diseases in 
animals which have some immune deficiency with allergic 
components. 
